Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.11.05.622098

Maximizing meiotic crossover rate reveals the map of Crossover Potential

Abstract

Meiotic crossovers are limited in number and unevenly distributed along chromosomes, both features often differing between sexes. The mechanisms imposing a different crossover landscape in female and male meiosis remain elusive. Here, we simultaneously disrupted multiple anti-crossover mechanisms in Arabidopsis and analyzed the whole genome sequence of thousands of female- and male-derived progenies. The largest crossover increase was reached in zyp1 recq4, with 12-fold in females and a 4.5-fold increase in males. Despite this unprecedented level of crossovers, fertility is marginally affected, opening new possibilities for plant breeding. Manipulating additional crossover regulators in zyp1 recq4 did not further elevate the frequency of crossovers, but modified the relative contributions of the two known crossover pathways. This suggests an upper limit was reached and the two pathways compete for a large but limited set of recombination intermediates. Remarkably, while wild-type crossover distribution differs markedly between sexes, the crossover landscapes of diverse mutants in both females and males converge to a single novel profile, which we termed Crossover Potential (COP). The COP profile, which we defined using 49,482 crossovers, can be accurately predicted using only sequence divergence and chromatin features. We propose that the COP represents the density of eligible recombination precursors, which is determined by genomic features and is thus identical in females and males. It suggests that the sexual dimorphism in the crossover landscape results exclusively from differential regulation of the likeness of precursors to mature into crossovers.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jing, J., Lian, Q., Durand, S., mercier, r.. 2024-11-07. Maximizing meiotic crossover rate reveals the map of Crossover Potential. https://doi.org/10.1101/2024.11.05.622098

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗